Drug intelligence / Profile preview

PNB-102

Development stage: Preclinical
Lead developer: PNB Vesper Life Sciences
Modality: Small Molecules

Overview

PNB-102 is a preclinical small molecule cholecystokinin B (CCK-B) receptor antagonist being developed by PNB Vesper Life Sciences for the treatment of Parkinson's disease and other central nervous system (CNS) disorders. As a chlorinated analog of PNB-101, PNB-102 is designed with increased lipophilicity to facilitate blood-brain barrier penetration. It is intended to target neuro-inflammation and modulate dopaminergic pathways in the brain.

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on PNB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNB-102.